title: Effects of single doses of alpidem, lorazepam, and placebo on memory and attention in healthy young and elderly volunteers.
abstract: The aim of the present study was to compare the effects of alpidem, a new imidazopyridine derivative with benzodiazepine-like anxiolytic effects, with those of lorazepam and placebo on memory and attention in two age groups of healthy volunteers. The study design was that of a randomized double-blind crossover trial with 12 young (18-30 years old) and 12 elderly (65-80) subjects. At weekly intervals, each subject was administered single oral doses of 25 mg alpidem, 50 mg alpidem, 1 mg lorazepam, and placebo in a randomized sequence. Computerized memory and attention tests were performed 90 minutes before and 320 minutes after drug administration. Lorazepam and alpidem 50 mg produced memory impairments: for verbal memory tests the difference against placebo was highly significant for both drugs, while for visual memory this impairment was significant for lorazepam only. No memory effects were seen with 25 mg alpidem. There were no significant drug effects on attention, suggesting a specific amnestic effect not explained by general sedation. Performance of the elderly subjects was much lower than that of the younger ones in both memory and attention tasks. It was not possible to observe any interaction effects between drug and age.
authors.affiliation: Psychiatric Hospital, University of Munich, FRG.
authors.forename: W
authors.initials: W
authors.lastname: Satzger
authors.forename: R R
authors.initials: RR
authors.lastname: Engel
authors.forename: E
authors.initials: E
authors.lastname: Ferguson
authors.forename: H
authors.initials: H
authors.lastname: Kapfhammer
authors.forename: F X
authors.initials: FX
authors.lastname: Eich
authors.forename: H
authors.initials: H
authors.lastname: Hippius
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D000647:Amnesia / Q000139:chemically induced / Q000523:psychology; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000494:pharmacology*; D001288:Attention / Q000187:drug effects*; D003071:Cognition / Q000187:drug effects; D004192:Discrimination, Psychological / Q000187:drug effects; D004311:Double-Blind Method; D004644:Emotions / Q000187:drug effects; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology*; D008140:Lorazepam / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D008568:Memory / Q000187:drug effects*; D011725:Pyridines / Q000009:adverse effects / Q000494:pharmacology*; D011897:Random Allocation; D012016:Reference Values
chemical_list: D014151:Anti-Anxiety Agents; D007093:Imidazoles; D011725:Pyridines; C052036:alpidem; D008140:Lorazepam